Abstract
Receptor activator of nuclear factorκB ligand (RANKL) has been shown to drive proliferation and migration in lung cancer; however, its role in KRAS-mutant (KRAS-MT) lung adenocarcinoma (LUAD) is not fully elucidated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have